From: Ginsenosides emerging as both bifunctional drugs and nanocarriers for enhanced antitumor therapies
Formulation | Product | Prescription (mole ratio) | Application | References |
---|---|---|---|---|
Doxorubicin HCl liposomes injection | Doxil® | HSPC/CHOL/DSPE-mPEG2000 (3:1:1) | Ovarian cancer; metastatic breast cancer; multiple myeloma | |
Vincristine sulfate liposomes injection | Marqibo® | SM/CHOL (3:2)a | Acute lymphoblastic leukemia; refractory cancer | |
Irinotecan hydrochloride liposome injection | Onivyde® | DSPC/CHOL/mPEG2000-DSPE (430:285:3)b | Pancreatic cancer | [165] |
PTX liposomes | NA | EYPC/Rh2 (10:3) | 4T1 breast carcinoma | [25] |
PTX liposomes | NA | EPC/Rg3 (10:3) | C6 murine glioma cells | [28] |
PTX liposomes | NA | EYPC/Rh2 (10:3) | Gastric cancer | [26] |
PTX liposomes | NA | EYPC/Rg3 (5:2) | Gastric cancer | [26] |
PTX liposomes | NA | EYPC/Rg5/soybean oil (10:4:5) | Gastric cancer | [26] |
PTXginposome | NA | Lecithin/Rg5 (5:2) | HGC-27; A549; MCF-7 | [27] |